Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 Ceritinib
0.001
ALK
RTK
 1.0262 0.00729
PDXHCI002 Neratinib
0.1
EGFR/HER2
RTK
 0.5417 -0.01033
MCF 10A Cediranib
0.31623
VEGFR/cKIT
RTK
 1.0087 -0.00055
PDXHCI002 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.2469 0.04779
SK-BR-3 Tivantinib
0.001
MET
RTK
 1.0421 0.00349
MCF 10A Cediranib
0.01
VEGFR/cKIT
RTK
 1.0016 -0.00009
PDXHCI002 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.4324 0.52102
PDXHCI002 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0508 0.00411
SK-BR-3 Neratinib
0.00031623
EGFR/HER2
RTK
 0.8693 0.01462
SK-BR-3 Ceritinib
3.1623
ALK
RTK
 -0.0418 0.08104
MCF 10A Tivantinib
3.1623
MET
RTK
 -0.0788 0.33510
MDA-MB-134-VI Ceritinib
0.001
ALK
RTK
 1.2398 -0.01049
MDA-MB-134-VI Ceritinib
0.01
ALK
RTK
 1.2351 0.00540
MDA-MB-134-VI Ceritinib
0.031623
ALK
RTK
 0.8743 0.01920
MDA-MB-134-VI Ceritinib
0.1
ALK
RTK
 0.5699 0.06305
MDA-MB-134-VI Ceritinib
1.0
ALK
RTK
 -0.2784 0.17358
MDA-MB-134-VI Neratinib
0.001
EGFR/HER2
RTK
 1.3618 -0.00624
MDA-MB-134-VI Neratinib
0.0031623
EGFR/HER2
RTK
 1.1587 0.00073
MDA-MB-134-VI Neratinib
0.1
EGFR/HER2
RTK
 1.2769 -0.00808
MDA-MB-134-VI Tivantinib
0.001
MET
RTK
 1.1350 -0.00700
MDA-MB-134-VI Tivantinib
0.0031623
MET
RTK
 1.2792 0.00506
MDA-MB-134-VI Tivantinib
0.01
MET
RTK
 1.0707 -0.00712
MDA-MB-134-VI Tivantinib
0.1
MET
RTK
 0.7452 0.06726
MDA-MB-134-VI Tivantinib
10.0
MET
RTK
 -0.6776 0.42976
MDA-MB-134-VI Cediranib
0.001
VEGFR/cKIT
RTK
 1.3158 -0.01192